Processing and Effects of Cannabis

A Double-Blind, Randomised, Placebo-Controlled, Cross-Over Study on the Pharmacokinetics and Effects of Cannabis

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00225407

Enrollment

Registered

2005-09-23

Start date

2005-07-31

Completion date

2005-12-31

Last updated

2005-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension, Tachycardia

Keywords

Cannabis, Tetrahydrocannabinol, Pharmacokinetics, Psychomotor tests, Event related potentials

Brief summary

The purpose of this study is to investigate the processing of cannabis, and to investigate the occurrence of effects of cannabis on the cardiovascular system and the central nervous system; at higher levels of exposure.

Detailed description

In Europe, cannabis is the most illicit used drug, mainly for its psychoactive properties (becoming high or stoned). The active compound in cannabis is THC (tetrahydrocannabinol). In recent years the strength of cannabis (marihuana) available on the market in the Netherland has increased (especially netherweed). The THC-content has increased from on average 8.6% in 2000 to on average 20.3% in 2004. Experienced users adapt their habit of smoking to the strength of the cannabis sigaret (joint). However, there is also a group of people, mainly young ones, who intent to smoke the joint entirely, and can therefore be exposed to higher levels of THC. Information is lacking about the effects of cannabis at higher levels of exposure. Because of this, the Ministry of Health, Welfare, and Sports of the Netherlands ordered the investigators to perform a study to gain more insight in this issue.

Interventions

DRUGSmoking of cannabis cigarettes (different strength)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Cannabis users (2-9 joints per month)

Exclusion criteria

* Psychiatric illness * Evidence of excessive alcohol abuse * Use of other drugs

Design outcomes

Primary

Measure	Time frame
Serum concentration over time	—
Physical parameters (heart rate, blood pressure)	—
Psychomotor tests (such continuous attention)	—
Event related potentials	—

Secondary

Measure	Time frame
Self-reporting questionnaires	—

Countries

Netherlands

Contacts

Primary ContactTjeert T Mensinga, MD, PhD

tjeert.mensinga@rivm.nl+31 30 2507340

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026